Last reviewed · How we verify

Vaxxinity, Inc. — Portfolio Competitive Intelligence Brief

Vaxxinity, Inc. pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
BNT162b2 vaccine BNT162b2 vaccine marketed Not specified Not specified Infectious Disease
ChAdOx1-S vaccine ChAdOx1-S vaccine phase 3 Viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease
Sinopharm BIBP Sinopharm BIBP phase 3 Inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bharat Biotech International Limited · 2 shared drug classes
  2. Crucell Holland BV · 2 shared drug classes
  3. Pfizer · 2 shared drug classes
  4. CanSino Biologics Inc. · 1 shared drug class
  5. Boryung Pharmaceutical Co., Ltd · 1 shared drug class
  6. Cellid Co., Ltd. · 1 shared drug class
  7. Centers for Disease Control and Prevention · 1 shared drug class
  8. BioNTech · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Vaxxinity, Inc.:

Cite this brief

Drug Landscape (2026). Vaxxinity, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vaxxinity-inc. Accessed 2026-06-10.

Related